Questions About Cancer? 1-800-4-CANCER

Breast Cancer Screening (PDQ®)

Health Professional Version
Last Modified: 06/19/2014

Changes to This Summary (06/19/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Breast Cancer Screening Modalities—Mammography

Revised text to state that the following Breast Imaging Reporting and Data System (BI-RADS) categories are used for reporting mammographic results: 0 for incomplete, 1 for negative, 2 for benign, 3 for probably benign, 4 for suspicious, 5 for highly suggestive of malignancy, and 6 for known biopsy or proven malignancy (cited D'Orsi et al. as reference 3).

Added text to state that the chance that biopsy will indicate malignant disease differs by BI-RADS classification; results from a series of 1,312 needle localizations that occurred as a result of a BI-RADS assignment other than 1 or 2 indicated the following chance of malignancy: category 0, 13%; category 2, 0%; category 3, 2%; category 4, 30%; or category 5, 97%.

Mammography—Variables Associated with Accuracy

Added text to state that for women aged 49 to 54 years, the recall rates for digital screens versus film screens were 2.7% versus 2.0%, respectively; the detection rates were 5.1% versus 4.0%, respectively; and the PPV was 21.4% versus 22.1%, respectively; however, for women aged 55 to 74 years, the recall rates for digital screens versus film screens were 1.7% versus 1.4%, respectively; the detection rates were 6.2% versus 5.6%, respectively; and the PPV was 35.7% versus 40.1%, respectively.

Harms of Screening Mammography

Added text to state that estimates of the extent of overdiagnosis noted in the Canadian National Breast Screening Study, a randomized clinical trial, have been reported; at the end of the five screening rounds, an excess of 142 invasive breast cancer cases was diagnosed in the mammography arm, compared with the control arm (cited Miller et al. as reference 19).

This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.